Summary: So far, soluble fibronectin has been quantitated mostly by immunological techniques. In this investigation we show that an immunological assay provides reliable results only with intact fibronectin. Fibronectin fragments resulting from proteolysis give rise to falsely raised values. We present four functional tests based on the sandwich (ELISA) technique on microtitre plates. These quantify fibronectin on the basis of its binding capacity to collagen, heparin/fibrin and carboxy-group-modified IgG with high sensitivity, specificity and precision. Analysis of the bioactivity spectrum of intact fibronectin is not disturbed by fibronectin fragments. Furthermore we demonstrate interferences, in particular between heparin and collagen in their mutual binding to fibronectin. This provides new indications of a "substrate activation" of fibronectin.
Introduction
fibronectin (M T = ca. 440000) is a dimer with two Fibronectin is the term used today for a high molecu-polypeptide chains connected via two disulphide lar weight glycoprotein, which has previoüsly been bridges. Additional intrachain S-S bridges contribute known under various names. The protein is of great to the formation of a typical tertiary structure characinterest for biochemical studies in cell biology and terized by four globular domains with protease-sensimedicine (l, 2, 3). The molecule is synthesized by tive connecting units. The glycosylation and phosvarious types of cells and is localized on the cell phorylation of the protein can show maturation-and surface äs a fibrillar polymer. The soluble plasma organ-specific variations (3, 5, 6).
Köttgen et al.: Functional anaiysis of plasma fibronectin
The domains mentioned above can be isolated by limited proteolysis (7, 8) . The domains are characterized by their differing capacity for binding primarily either collagen, glycosaminoglycans (especially heparin) and fibrin, with additional affinities to complement factor Clq, actin, DNA and gangliosides. The C-terminal domain additionally binds proteins with modified carboxyl groups such äs IgG (9, 10) .
Due to these multiple ligand properties, fibronectin is involved in many biological functions, such äs cell adhesion, chemotaxis, immunomodulation, bacterial tissue tropism, wound repair and in blood coagulation (2) . Fibronectin is gaining additional medical significance, since appreciable alterations of the plasma fibronectin concentrations can be observed in the plasma of patients with inflammatory diseases äs well äs in shock patients (11, 12, 13) .
In addition, the differentiation of a 'malignant' from a 'benign' ascites is possible by determining the fibronectin concentration in ascites (14) . However, the majority of these results is based exclusively on immunological quantification of fibronectin in which altered functionality of the various domains is not reflected. Furthermore, these investigations do not take into consideration the extent to which functionreduced proteolytic fibronectin fragments may influence the quantitation of intact fibronectin. Enhanced proteolytic activity can be found for example in malignant ascites, äs well äs in the plasma of patients with acute pancreatitis or disseminated intravascular coagulation with fibrinolytic states.
In the results presented, we describe a test battery based on an ELISA-equivalent test procedure enabling quantification of four domain-specific functions of fibronectin. Furthermore, we present comparative investigations on functional interference with the fibronectin binding capacity.
Materials and Methods
Rabbit anti-human fibronectin and rabbit anti-human-fibronectin-peroxidase conjugate were obtained from Dakopatts (Copenhagen, Denmark), thermolysin from Boehringer (Mannheim, FRG), thrombin from Behringwerke (Marburg, FRG), bovine serum albumin and 3,3', 5,5'-tetramethylbenzidine (rom Miles Lab. (Munich, FRG), and hydroxyapatite (DNA grade) from Bio Rad (Munich, FRG). -Aminocaproic acid, heparin-agarose, peroxidase, heparin-sodium salt, gelatine (calf skin), fibrinogen (bovine), glycine ethyl ester, Tween 20 and 3-amino-9-ethylcarbazole were obtained from Sigma (Munich, FRG), gelatine-sepharose from Pharmacia (Uppsala, Sweden), nitrocellulose membranes (0.45 pore size) from Biotec Fischer (Reiskirchen, FRG). Ali other reagents were purchased äs analytical grade from E. Merck (Darmstadt, FRG). 
Fibronectin Isolation
Fibronectin was prepurified from citrate-plasma by afrraity chromatography on gelatine-sepharose in buffer (i) with 10 mmol/1 -aminocaproic acid, 5.0 mmol/1 EDTA fpliowed by a specific elution with 50 mmol/1 Tris, 4 mol/1 urea, pH 7.6.
The fibronectin was additionally purified on heparin-sepharose (washing buffer: 10 mmol/1 Tris* pH 7.6; elution: 10 mmol/1 Tris, 0.5 mol/1 NaCl, pH 7.6) (15). In the SDS-pplyacrylamide gel electrophoresis, the typical double bands are found exclusively at M T = 220000. The protein determination is carried out according to Lowry or by phptometric measurement at 280 nm (fibronectin [10 g/l] A 2 eo <1 cin> = 12.8) (16) . After addition of NaN 3 (0.1 g/l) the purified protein can be stored at 4 °C for at least eight weeks.
Fibronectin proteolysis
Thermolysin and fibronectin l : 200 (weight ratip) were bated for different times (see results) at 20 °C in 60 mmol/1 Tris, 3.0 mmol/1 CaCl 2 , pH 7.6 (7). The proteolysis is terminated by addition of 0.2 mol/1 EDTA (final concentration in the test mixture 10 mmol/1 EDTA).
Polyacrylamide gel electrophoresis
The SDS-polyacrylamide gel electrophoresis was carried out under reducing conditions in the buffer System according to Läemmli (20) with a 3.5% stacking gel, a linear gradient-gel (5-12%) and a Separation distance of 13 ein. The proteins were fixed and stained in a solution containing acetic acid (70 g/l) -methanol (l + 2 by vol.) and Coomassie blue (1.0 g/l).
Western blot
Proteins were transferred from the polyacrylamide gel electrophoretically at 100 volts for one hour onto nitrocellulose sheets according to Towbin (19) . After blocking the free binding sites on the nitrocellulose membrane for 16h (blocking buffer see above), the membrane was incubated for l h with shaking in a l : 1000 dilution (by vol.) of perojcjdase-labeled antibody in buffer (ii). After washing three times in buffer (iii), the menv brane was stained with aminoethylcarbazole.
Hydroxyapatite chromatography
Fibronectin was equilibrated in washing buffer (2 mmol/1 sodium phosphate buffer, l mmol/1 EDTA, pH 6.8) and 100 mg protein was applied to the column (l .5 χ 25 cm). The specific elution was carried out in a linear gradient up to 200 mmol/1 sodium phosphate (18) .
Enzyme-linked-immuno-sorbent-assays (ELISA)
The assays were performed in accordance with the "sandwich technique" with biological ligands fixed to polystyrene. For detection of bound fibronectin, peroxidase-conjugated antifibronectin was used. Tetramethylbenzidine (80 mg/I dissolved in 160 mmol/1 acetate/citrate buffer, 1.3 mmol/1 H 2 O 2 , pH 6.0) served s Substrate. The product formation at 25 °C was quantified after 20 min at 620 nm. AU washing proccdures were identical in the subsequent tests.
Antibody assay
Pipette 100 μΐ antibody solution (rabbit anti-human fibronectin, diluted l : 2000 with phosphate buffer (i)) into the wells and incubate for 16 h at 4 °C for adsoφtion. Wash the plates three times with buffer (iii), then add a sample of 150 μΐ (diluted in buffer (ii)). For plasma, dilution to 1:10000 is necessary. Incubate the test mixture for 2.5 h at 25 °C and wash three times with buffer (iii). Add 125 μΐ peroxidase labeled antibody (l : 1000 diluted in buffer (ii)), incubate for one hour at 25 °C and wash again three times with buffer (iii). Add 125 μΐ Substrate solution and measure the product formation s described above.
Heparin assay
Transfer 100 μΐ of heparin solution (100 U/l = 0.6 g/l in phosphate buffer (i)) into the wells s described above. Add 120 μΐ sample material (dilution in buffer (ii); for plasma samples l: 1000). Further procedure s above.
Fibrin assay
Bovine fibrin is used s ligand. For this purpose, the microtitre plate is coated with fibrinogen, which is subsequently degraded to fibrin by thrombin. Since the fibrinogen preparation is contaminated with fibronectin, and hence cross-reacts with the antibody used, fibrinogen must be purified by affinity chromatography on gelatine-sepharose (see above).
Place 100 ul purified fibrinogen solution (0.1 g/l in phosphate buffer (i)) into the wells and incubate over 3 h at 25 °C in a moist chamber. After triple washing add 125 ul thrombin solution (0.4 U/ml in phosphate buffer (i)) and incubate the plates for 16 h at 4 °C. After finishing the washing Steps s described above, add 120 μΐ diluted sample (in phosphate buffer (ii)); for plasma samples dilute l: 100 and proceed s described.
Carboxyl group-modified IgG assay
Human immunpglobulin IgG is modified at the carboxylgroups (IgG mo< |) by coupling glycine ethyl ester to the protein in the presence of carbodiimide (9, 17) . Add 100 μι of the modified IgG (10 mg/1 in phosphate buffer (i)) s ligand to the solid phase. After washing, pipette 120 μΐ diluted sample (plasma l : 1000) into the wells and incubate for 90 min, In this test, add 2.5% (by vol.) rabbit serum to the enzyme-labeled antibody in order to ayoid the nonspecific binding of the antibody to the modified IgG. The further quantification of binding is carried out s described.
Gelatine assay
Cover the microtitre plates with 100 μΐ gelatine solution (2.5 g/l in phosphate buffer (i)). The further procedure is s described in the antibody assay. Plasma samples are diluted l : 10000.
For the analysis of plasma, EDTA-plasma with addilion of l TlU/ml (trypsin inhibiting unit) aprotinin (Trasylol®) is generally used. For the comparative immunoturbidimetric fibronectin quantification, the 'Fibronectin' test kit from Boehringer (Mannheim, FRG) is used.
Results
As a basis for the following function-specified binding assays, we determined fibronectin in the ELISA test on microtitre plates (antibody assay). We used both purified fibronectin s well s plasma samples. With both materials, the fibronectin concentration can be quantified over a concentration r nge of l μg/l to 32 μg/l. This means a detection limit of 0.16 ng fibronectin. The typical shape of the Standard curve is shown in figure 1. In this s well s the other Systems, the absorbance of the lowest detectable fibronectin concentration is defined s the threefold Standard deviation of the blank value.
Since the immunological reactivity of fibronectin cannot provide reliable information on alterations of defined fibronectin functions, we developed different ELISA-equivalent procedures, each one quantifying a specific fibronectin binding property. In all assays the microtitre plates were first coated with the specific ligand, then incubated with the fibronectin-containing sample. The ligand-bound fibronectin was quantified by a peroxidase-labeled anti-fibronectin antibody. After lyophilisation, all ligand-coated carriers can be stored at 4 °C for at least eight weeks.
The collagen-binding capacity of fibronectin was tested in the gelatine assay. Figure l shows the typical calibration curve. The measuring r nge extends from 1.6 μg/l-50 μ%/1. This corresponds to a detection limit of 0.2 ng fibronectin per well.
The fibronectin-heparin affinity was quantified via an appropriate test System. The measuring r nge here was 200 μg/l -125 mg/1 (detection limit 24 ng fibronectin).
We found the fibrin binding assay to have the lowest sensitivity (3 mg/1-200 mg/1; detection limit 0.36 μg fibronectin).
Since fibronectin possesses an additional binding site for carboxyl group-modified proteins in its C-terminal domain, we developed an assay for these ligands. As can be seen from figure l, we found that this assay gave the widest measuring r nge (25 μ^ -1.6 mg/1) and a good limit of detection (3.0 ng fibronectin). phase. All Systems showed aii optimal binding in phosphate buffer containing bovine serum albumin and EDTA and a broad pH optimum between pH 7.0 and 8.0. An exception was the IgG mod assay. Here, we found a pH optimum at 6.0.
According to various investigations, raised ion concentrations will abolish heparin-fibronectin binding. The addition of 0.15 mol/1 NaCl to the phosphate buffer leads to an almost complete loss of fibronectin binding to solid phase-tdünd heparin (data not shown here).
To check the binding specificities, we performed assays in the presence of heparin, fibrinogen or gelatine ( fig. 2 ). These tests were carried out with purified fibronectin. The fibrin assay was influenced by fibrinogen, but not by gelatine or heparin. It has to be mentioned here that the affinity of native fibrinogen to fibronectin compared with that of fibrin is only three percent (data not shown here). The gelatine assay was inhibited by gelatine and remained unäf-fected by heparin and fibrinogen. The heparin assay was moderately stimulated by heparin, highly activated by gelatine and not affected by fibrinogen. The binding assay for modified IgG was not altered by any of the tested substances. Native IgG did not influence any of the tests mentioned. To check the immune reactivity and bioactivity of fibronectin fragments, we incubated fibronectin with thermolysin for various periods of time. The resulting polypeptide chains were separated by polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Western blot). Figure 5 shows that thermolysin treatment of fibronectin leads, in time-dependent fashion, to an increasing cleavage of the protein.
Whereas some polypeptide fragments down to a molecular weight of M r = ca. 30 000 were still immunoreactive, various larger fragments did not react with anti-fibronectin. To support this finding, thermolysintreated fibronectin was separated on a hydroxyapatite column. With this technique it is possible inter alia to isolate the gelatine domain (M r = 43000) (18) . The isolated peptide fragment was seen in the polyacrylamide gel electrophoresis after Coomassie staining at the expected molecular weight; however, it could not be demonstrated immunologically in the Western blot ( fig. 5 ). The isolated peptide likewise did not react in the gelatine assay (data not shown here). However, we have indications that this isolated fibronectin fragment can be quantified on the basis of its carbohydrate moiety by an enzyme-linked lectin assay (manuscript in preparation).
Data presented in figure 6 document the influence of proteolysis on the binding assays and demonstrate at the same time whether fibronectin cleavage products enhancement of the measured concentration. We obtained almost identical false positive results with the commercial turbidimetric fibronectin-assay. Proteolysis with trypsin or subtilisin interfered similarily.
Compared with the antibody assay, the functional binding tests showed a quite difTerent picture. After 30 min of thermolysin treatment, all binding affinities were no longer detectable.
To examine the question of whether fibronectin fragments influence the functional quantification of intact fibronectin, we mixed equal parts of native fibronectin with fibronectin subjected to limited proteolysis. Fibronectin fragments did not have any activating or inhibiting effect on the gelatine, fibrin or IgG assay ( fig. 6 ). On the other band, in the heparin binding test the low molecular weight fibronectin fragments (after long thermolysin treatment) had a significant inhibitory effect on the heparin binding activity of native fibronectin.
In order to show to what extent the techniques presented here for human fibronectin can be transferred to investigations with fibronectin of animal origin, we tested plasma from rat, mouse, guinea pig, hamster, calf, dog, sheep and rabbit. In the Western blot, all samples, except rabbit plasma, showed immunoreactivity with anti-human fibronectin. We found no cross-reactivity with other proteins. Table 2 demonstrates that, with the exception of the fibrin binding assay, the ligand-specific test Systems can be applied to fibronectin studies in other animal species.
Tab. 2. Species-specificity of the fibronectin assays. In all assays EDTA plasma and anti-human fibronectin were used. Predilutions of the plasma samples are described in the text. The concentration and binding activities are calculated from the Standard calibration curves (see fig. 1 ). All values are the mean of triple determinations (-= no binding capacity). 
Discussion
In the present paper we describe highly sensitive ELISA techniques for quantification of fibronectin, together with studies on binding activities in biological materials. At the same time, we show that in many cases erroneous results are to be expected with merely immunological assays of the fibronectin concentration. Hitherto, the most frequently applied methods for the determination of fibronectin concentration in plasma, cerebrospinal fluid, synovial fluid or ascites have been immunological assays based on turbidimetry, laser nephelometry or rocket immunoelectrophoresis (21, 22, 23) . Nevertheless, problems in the quantification which greatly restrict the reliability of these methods have been known for sortie time (24) . A further major disadvantage of the immunological quantification is that these techniques cannot allow appraisals of the functional integrity of the molecule. Both these facts probably explain the contradictory opinions on the diagnostic and pathobiochemical relevance of fibronectin in various diseases (25, 26) . In view of these problems, other study groups have already presented suggestions for the functional analysis of fibronectin (15, 27, 28, 29) . In these gelatine and opsonin function-specified tests of fibronectin, the possible interferences of fibronectin domains have not been investigated. Other studies, however, show that heparin leads to an exposure of active domains via an alteration in conformation of the fibronectin molecule (30, 31 ).
The individual techniques described here are characterized by a high degree of sensitivity, good reproducibility and accuracy äs well äs good practicability. The antibody assay is not interfered with by other plasma proteins or other physiological plasma constituents. However, it must be born in mind that according to our results, äs already suspected by other authors (24) , proteolytic fibronectin fragments also expose increased amounts of immunoreactive determinants, so that fibronectin concentrations are over-estimated. Other fibronectin fragments are no longer immunoreactive (32) . We confirm these findings.
The question of the extent to which proteolytic fragments have false positive or false negative effects on the function tests could also be clarified. We show that all binding affinities are destroyed by sufficiently intensive exposure to proteases. At the same time, we document in additional experiments with intact fibronectin that late fibronectin fragments do not disturb the binding capacity of native fibronectin. An exception is the heparin assay. It shows a moderate Inhibition at a high fragment concentration.
To our knowledge, the described lest Systems present the widest spectrum for a functional analysis of fibronectin. At the same time, they provide the chance of testing interference of the individual ligands. For the quantification of the Collagen binding capacity we used gelatine from calf skin äs ligand. Other authors have shown that various collagen types possess a differentiated fibronectin binding behaviöur (33) . Since the collagen binding sites are localized in the two N-terminal domains of the fibronectin molecule and since fibrin and heparin are also bound in this region, it had to be checked in particular whether these two substances interfere with the gelatine binding assay. It becomes evident from our studies that soluble gelatine competitively inhibits the binding of fibronectin to the solid phase-bound gelatine. However, neither heparin nor fibrinogen influence the test. A highly function-specific test is thus provided. So far, it is not possible to assess how or to what extent the two domains with collagen binding affmity are involved in the gelatine test.
Fibronectin is bound covalently in the N-terminal domain to the -chain of the fibrin monomer via the transglutaminase activity of factor XIII. This binding has no significance in our investigations with purified fibronectin. In addition, the neighboring domain binds fibrin, and it binds fibrinogen with reduced affmity. Since collagen is also bound in this region, our demonstration that the fibrin assay is preferentially inhibited by fibrinogen, and to a lesser extent also by gelatine, is understandable.
The binding affinity of fibronectin to carboxyl groupmodified IgG appears to be especially interesting, since only the C-terminal domain is thought to be responsible for this affinity (9) . Otherwise only fibrin (which does not interfere in any way with this test System) is known to bind at this site. The specificity of this binding also becomes evident, in that native IgG does not have any influence. In clinical terms, this test will be important, since there are indications that the opsonin function of fibronectin involves this binding type (34) .
Glycosaminoglycans are bound by two domains of the intact fibronectin molecule. An additional binding domain is rendered reactive by limited proteolysis (8) . Whereas native fibronectin almost exclusively binds heparin fragments of fibronectin can also bind other proteoglycans with variable affinity. In the present investigation, we were concerned only with heparin. The N-terminal heparin-binding site is Ca 2 +-inhibited, it can be assumed that mainly the N-terminal binding site is detected in this heparin assay. Fibrinogen does not interfere in the heparin assay.
Soluble heparin promotes fibronectin affinity to solid phase-bound heparin at low conceiitration and inhibits this competitively at higher concentrations. However, soluble gelatine induces a very impressive, concentratioü-dependent enhancement of fibronectin binding to the carrier-bound heparin. In cell adhesion studies, an equivalent effect has already been observed and designated äs "Substrate activation". Heparin also significantly stimulates the fibronectin-mediated uptake of gelatine-cöäted particles by macrophages (36) . Thus, we have positive indications that the results of our test system can be transferred to studies in cell biology.
Further investigations are required to show to what extent the effects observed here are also relevant for in vivo functional regulation. This not only applies to cell biological studies with use of additional ligands and inhibitors, but also to the possible therapeutic use of fibronectin in various 'active forms'. Positive and negative reports on the use of fibronectin in shock treatment and wound healing so far indicate that further basic work is necessary (37, 38) . Diagnostic use of the fibronectin function tests described here also open new possibflities in the context of inflammation and turnour diagnosis. Orientative investigations on plasma samples of patients with liver diseases äs well äs of tumour patients suggest the existence of marked differences and variations of the fibronectin functional spectrum.
Finally, it is documented that the test System can also be used for functional analysis of fibronectin of other animal species, when using the appropriate animal fibronectin Standards. Due to the high degree of assay sensitivities, only minimal sample amounts are needed. At the same time, these investigations already show that fibronectins from different species have a significantly different functional spectrum, showing comparable concentrations in the antibody assay (except dog) and significantly differing ratios between the specific binding assays.
